Hematologic Diseases: Clinical Trials

1,442 trials for Hematologic Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1442 completed. 1442 Phase 3, 147 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 31442Completed 1442
Phase 2147Completed 147

Follow Hematologic Diseases: new trials by email Literature Review of Hematologic Diseases trials Research Report on Hematologic Diseases

Trials (filtered) newest first · largest first

All 1,442 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Probiotics Against Erythropoietin Resistance in Chronic Kidney Disease Patients.
Erythropoietin + Probiotic, EPO - Anaemia, Chronic Kidney Disease
Phase 3CompletedBadr University802026-02-012026-10-30
Efficacy and Safety of HSK39297 in Anti-C5 Treated PNH Patients With Anemia
HSK39297 tablets - Paroxysmal Nocturnal Haemoglobinuria (PNH)
Phase 3CompletedHaisco Pharmaceutical Group Co., Ltd.362025-05-122026-02-11
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
ICS-LABA, benralizumab, Placebo for Benralizumab - Eosinophilic Asthma
Phase 3CompletedAstraZeneca1302025-03-282026-10-16
Zinc for Infection Prevention in Sickle Cell Anemia-2 (ZIPS-2)
zinc sulfate, Placebo - Sickle Cell Disease
Phase 2 / Phase 3CompletedIndiana University1002025-02-102026-01-30
Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products
Recombinant single-chain factor VIII (rVIII-SingleChain) - Congenital Hemophilia A
Phase 3CompletedCSL Behring622025-01-092026-10-23
Efficacy and Safety of HRS-5965 in Patients With PNH Who Are Still Anemia After Anti-C5 Antibody Treatment
HRS-5965 capsule - Paroxysmal Nocturnal Hemoglobinuria
Phase 3CompletedChengdu Suncadia Medicine Co., Ltd.392025-01-072026-01-08
Effectiveness of Oral Iron Therapy in Iron Deficiency Anemia With Daily vs Alternate Day Dosing
Ferrous sulphate - Iron Deficiency Anemia, Iron Deficiency Anemia Treatment
Phase 3CompletedUniversity of Child Health Sciences and Children's Hospital, Lahore602025-01-072026-06-16
A Study to Evaluate the Efficacy and Safety of Oral HRS-5965 in Adult Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy
HRS-5965 capsule, Eculizumab Injection - Paroxysmal Nocturnal Hemoglobinuria
Phase 3CompletedChengdu Suncadia Medicine Co., Ltd.762024-10-252025-09-11
Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Ravulizumab - Paroxysmal Nocturnal Hemoglobinuria, PNH
Phase 3CompletedAlexion Pharmaceuticals, Inc.182024-10-102026-06-05
Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX Therapy
Recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) - Hemophilia B
Phase 3CompletedCSL Behring232024-07-282026-07-23
Safety and Effectiveness of IHAT in Iron Deficient Pre-menopausal Woman
Low dose IHAT, High Dose IHAT, Carob flour - Iron-deficiency
Phase 3CompletedRDC Clinical Pty Ltd1802024-03-062025-03-10
Safety and Effectiveness of Iron Hydroxide Adipate Tartrate (IHAT) in Iron Deficient Premenopausal Women
Low Dose IHAT, High Dose IHAT, Carob Flour - Iron-deficiency
Phase 3CompletedNemysis Ltd1802024-03-052025-06-04
Comparative Analysis of Oral Iron With Injectable Ferric Carboxymaltose for Post Partum Iron Deficiency Anaemia
Ferric Carboxymaltose (FCM) - Anemia, Anemia, Postpartum
Phase 2 / Phase 3CompletedESI-PGIMSR, Basaidarapur2002024-03-012026-06-15
STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma
Benralizumab - Severe Eosinophilic Asthma
Phase 3CompletedAstraZeneca5042024-02-282026-09-03
Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
FRSW117 - Severe Hemophilia A
Phase 3CompletedHangzhou Gensciences Biopharmaceutical Co., Ltd.1242023-12-272026-09-09
Intravenous Iron Versus Oral Iron for the Treatment of Iron Deficiency Anemia
Venofer 200 MG Per 10 ML Injection, Ferrous sulfate - Iron Deficiency Anemia of Pregnancy
Phase 3CompletedArrowhead Regional Medical Center5182023-11-212026-11-09
Comparison of the Efficacy and Safety of Venetoclax in Combination With 3 Days Decitabine (DEC3-VEN) vs. Venetoclax in Combination With Azacitidine (VIALE-A) in the Treatment of Elderly Patients or Unfit, New-diagnosis Acute Myeloid Leukemia Patients
Experimental: Venetoclax in combination with Decitabine (+-sorafenib), Active Comparator: Standard dose of Venetoclax + Azacitidine - Elderly AML Patients, Unfit, New-diagnosis AML
Phase 3CompletedThe Second Affiliated Hospital of Kunming Medical University1542023-11-012026-09-09
A Study to Evaluate P1101 in Japanese PV Patients
P1101, Low-dose aspirin, Phlebotomy - Polycythemia Vera (PV)
Phase 3CompletedPharmaEssentia Japan K.K.212023-10-172024-11-08
Study of SAL-0951 Compared to Recombinant Human Erythropoietin in Anemic Patients Receiving Maintenance Hemodialysis
SAL-0951 tablets, rHuEPO injection - Anemia
Phase 3CompletedShenzhen Salubris Pharmaceuticals Co., Ltd.1002023-09-192024-12-06
Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P)
Daprodustat - Anaemia
Phase 3CompletedGlaxoSmithKline42023-09-062025-11-10

Showing 20 of 1442. Sign in to see all of them.

Narrower conditions

Anemia (264)  ·  Multiple Myeloma (197)  ·  Leukemia, Myeloid, Acute (153)  ·  Leukemia (131)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (111)  ·  Hemophilia A (99)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (97)  ·  Myelodysplastic Syndromes (82)  ·  Purpura, Thrombocytopenic, Idiopathic (68)  ·  Lymphoma (66)  ·  Renal Insufficiency, Chronic (66)  ·  Anemia, Iron-Deficiency (61)  ·  Neoplasms (54)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (49)

Broader conditions

Hemic and Lymphatic Diseases (1442)  ·  Neoplasms (594)  ·  Neoplasms by Histologic Type (566)  ·  Immune System Diseases (518)  ·  Hemorrhagic Disorders (456)  ·  Pathological Conditions, Signs and Symptoms (435)  ·  Pathologic Processes (413)  ·  Immunoproliferative Disorders (383)  ·  Lymphoproliferative Disorders (380)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (293)  ·  Disease Attributes (279)  ·  Cardiovascular Diseases (262)  ·  Leukemia (259)  ·  Vascular Diseases (256)

Interventions

Dexamethasone (125)  ·  Cyclophosphamide (105)  ·  Cytarabine (103)  ·  Daunorubicin (58)  ·  Methotrexate (58)  ·  Darbepoetin alfa (55)  ·  Vincristine (53)  ·  Epoetin Alfa (49)  ·  Bortezomib (48)  ·  Lenalidomide (48)  ·  Prednisone (48)  ·  Etoposide (44)  ·  Rituximab (43)  ·  Doxorubicin (42)  ·  Mercaptopurine (39)

Sponsors

Hoffmann-La Roche (56)  ·  Amgen (52)  ·  Novartis Pharmaceuticals (38)  ·  Celgene (28)  ·  Children's Oncology Group (28)  ·  Baxalta now part of Shire (27)  ·  GlaxoSmithKline (24)  ·  CSL Behring (22)  ·  American Regent, Inc. (20)  ·  Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (20)  ·  Pfizer (20)  ·  Novo Nordisk A/S (19)  ·  Janssen Research & Development, LLC (17)  ·  National Cancer Institute (NCI) (17)  ·  M.D. Anderson Cancer Center (16)

Countries

United States (682)  ·  Germany (362)  ·  France (351)  ·  Italy (325)  ·  United Kingdom (312)  ·  Canada (307)  ·  Spain (301)  ·  Australia (241)  ·  Poland (230)  ·  Russia (198)  ·  Belgium (194)  ·  Austria (174)  ·  Netherlands (173)  ·  Czechia (167)  ·  Japan (163)

Results publications

PMID 36005278, PMID 36791280, PMID 26965694, PMID 34932836, PMID 38620092, PMID 39121442, PMID 40750723, PMID 41114449, PMID 19216617, PMID 23343061, PMID 23343062, PMID 26196195, PMID 31221778, PMID 34289038, PMID 35939785, PMID 36749544, PMID 37267439, PMID 37975597, PMID 38363466, PMID 40266025, PMID 40359056, PMID 19671919, PMID 22689675, PMID 23007406, PMID 24970932, PMID 26931631, PMID 28751558, PMID 31196847, PMID 31203241, PMID 31375516, PMID 33131249, PMID 33242441, PMID 33995988, PMID 34362786, PMID 34922648, PMID 35829925, PMID 36184192, PMID 36815378, PMID 36848635, PMID 37042865, PMID 37341189, PMID 37890117, PMID 38023148, PMID 38295280, PMID 38446568, PMID 39091324, PMID 39229471, PMID 39516087, PMID 40386832, PMID 40535755

NIH funding

2016 (34), 2014 (29), 2017 (25), 2009 (24), 2015 (18), 2008 (17), U10CA098543 (15), 2023 (14), 2018 (12), 2005 (11), 2019 (11), U10CA021115 (9), 2004 (7), U01HL069294 (7), U10CA032102 (6)